Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.

Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward

Announces restructuring program to support its expansion into precision cancer therapeutics

Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy

Performance of Trovera™ ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics

Seven new partners to commercialize Trovera™ liquid biopsy tests in Europe and the Middle East

Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution

Trovera™ liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively assess response to therapy

BCBS Illinois expands patient access to Trovera™ tests for 8.1 million covered lives